Cargando…

Identification of biomarkers specific to five different nicotine product user groups: Study protocol of a controlled clinical trial

BACKGROUND: Assessing biomarker profiles in various body fluids is of large value to discern between the sole use of nicotine products. In particular, the assessment of the product compliance is required for long-term clinical studies. The objective of this study was the identification of biomarkers...

Descripción completa

Detalles Bibliográficos
Autores principales: Sibul, Filip, Burkhardt, Therese, Kachhadia, Alpeshkumar, Pilz, Fabian, Scherer, Gerhard, Scherer, Max, Pluym, Nikola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219643/
https://www.ncbi.nlm.nih.gov/pubmed/34189337
http://dx.doi.org/10.1016/j.conctc.2021.100794
_version_ 1783710979033399296
author Sibul, Filip
Burkhardt, Therese
Kachhadia, Alpeshkumar
Pilz, Fabian
Scherer, Gerhard
Scherer, Max
Pluym, Nikola
author_facet Sibul, Filip
Burkhardt, Therese
Kachhadia, Alpeshkumar
Pilz, Fabian
Scherer, Gerhard
Scherer, Max
Pluym, Nikola
author_sort Sibul, Filip
collection PubMed
description BACKGROUND: Assessing biomarker profiles in various body fluids is of large value to discern between the sole use of nicotine products. In particular, the assessment of the product compliance is required for long-term clinical studies. The objective of this study was the identification of biomarkers and biomarker patterns in body fluids, to distinguish between combustibles, heated tobacco products, electronic cigarettes, oral tobacco and oral/dermal nicotine products used for nicotine replacement therapy (NRT), as well as a control group of non-users. METHODS: A controlled, single-center study was conducted with 60 healthy subjects, divided into 6 groups (5 nicotine product user groups and one non-user group) based on their sole use of the products of choice. The subjects were confined for 76 h, during which, free and uncontrolled use of the products was provided. Sample collections were performed according to the study time schedule provided in Table 2. The primary outcome will be validated through analysis of the collected biospecimens (urine, blood, saliva, exhaled breath and exhaled breath condensate) by means of untargeted omics approaches (i.e. exposomics, breathomics and adductomics). Secondary outcome will include established biomarker quantification methods to allow for the identification of typical biomarker patterns. Statistical analysis tools will be used to specifically discriminate different product use categories. RESULTS/CONCLUSIONS: The clinical trial was successfully completed in May 2020, resulting in sample management and preparations for the quantitative and qualitative analyses. This work will serve as a solid basis to discern between biomarker profiles of different nicotine product user groups. The knowledge collected during this research will be required to develop prototype diagnostic tools that can reliably assess the differences and evaluate possible health risks of various nicotine products.
format Online
Article
Text
id pubmed-8219643
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-82196432021-06-28 Identification of biomarkers specific to five different nicotine product user groups: Study protocol of a controlled clinical trial Sibul, Filip Burkhardt, Therese Kachhadia, Alpeshkumar Pilz, Fabian Scherer, Gerhard Scherer, Max Pluym, Nikola Contemp Clin Trials Commun Article BACKGROUND: Assessing biomarker profiles in various body fluids is of large value to discern between the sole use of nicotine products. In particular, the assessment of the product compliance is required for long-term clinical studies. The objective of this study was the identification of biomarkers and biomarker patterns in body fluids, to distinguish between combustibles, heated tobacco products, electronic cigarettes, oral tobacco and oral/dermal nicotine products used for nicotine replacement therapy (NRT), as well as a control group of non-users. METHODS: A controlled, single-center study was conducted with 60 healthy subjects, divided into 6 groups (5 nicotine product user groups and one non-user group) based on their sole use of the products of choice. The subjects were confined for 76 h, during which, free and uncontrolled use of the products was provided. Sample collections were performed according to the study time schedule provided in Table 2. The primary outcome will be validated through analysis of the collected biospecimens (urine, blood, saliva, exhaled breath and exhaled breath condensate) by means of untargeted omics approaches (i.e. exposomics, breathomics and adductomics). Secondary outcome will include established biomarker quantification methods to allow for the identification of typical biomarker patterns. Statistical analysis tools will be used to specifically discriminate different product use categories. RESULTS/CONCLUSIONS: The clinical trial was successfully completed in May 2020, resulting in sample management and preparations for the quantitative and qualitative analyses. This work will serve as a solid basis to discern between biomarker profiles of different nicotine product user groups. The knowledge collected during this research will be required to develop prototype diagnostic tools that can reliably assess the differences and evaluate possible health risks of various nicotine products. Elsevier 2021-06-02 /pmc/articles/PMC8219643/ /pubmed/34189337 http://dx.doi.org/10.1016/j.conctc.2021.100794 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Sibul, Filip
Burkhardt, Therese
Kachhadia, Alpeshkumar
Pilz, Fabian
Scherer, Gerhard
Scherer, Max
Pluym, Nikola
Identification of biomarkers specific to five different nicotine product user groups: Study protocol of a controlled clinical trial
title Identification of biomarkers specific to five different nicotine product user groups: Study protocol of a controlled clinical trial
title_full Identification of biomarkers specific to five different nicotine product user groups: Study protocol of a controlled clinical trial
title_fullStr Identification of biomarkers specific to five different nicotine product user groups: Study protocol of a controlled clinical trial
title_full_unstemmed Identification of biomarkers specific to five different nicotine product user groups: Study protocol of a controlled clinical trial
title_short Identification of biomarkers specific to five different nicotine product user groups: Study protocol of a controlled clinical trial
title_sort identification of biomarkers specific to five different nicotine product user groups: study protocol of a controlled clinical trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219643/
https://www.ncbi.nlm.nih.gov/pubmed/34189337
http://dx.doi.org/10.1016/j.conctc.2021.100794
work_keys_str_mv AT sibulfilip identificationofbiomarkersspecifictofivedifferentnicotineproductusergroupsstudyprotocolofacontrolledclinicaltrial
AT burkhardttherese identificationofbiomarkersspecifictofivedifferentnicotineproductusergroupsstudyprotocolofacontrolledclinicaltrial
AT kachhadiaalpeshkumar identificationofbiomarkersspecifictofivedifferentnicotineproductusergroupsstudyprotocolofacontrolledclinicaltrial
AT pilzfabian identificationofbiomarkersspecifictofivedifferentnicotineproductusergroupsstudyprotocolofacontrolledclinicaltrial
AT scherergerhard identificationofbiomarkersspecifictofivedifferentnicotineproductusergroupsstudyprotocolofacontrolledclinicaltrial
AT scherermax identificationofbiomarkersspecifictofivedifferentnicotineproductusergroupsstudyprotocolofacontrolledclinicaltrial
AT pluymnikola identificationofbiomarkersspecifictofivedifferentnicotineproductusergroupsstudyprotocolofacontrolledclinicaltrial